ArticleJournal of Korean Neurosurgical Society2026
Middle Meningeal Artery Embolization for Recurrent Chronic Subdural Hematoma.
Article in Journal of Korean Neurosurgical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRepeating surgical treatment remains the main option for recurrent chronic subdural hematoma, but a second recurrence frequently occurs. We employed middle meningeal artery embolization as an alternative treatment for recurrent hematoma. This study aimed to evaluate the effect and safety of middle meningeal artery embolization compared with conventional retreatment.
methodsWe retrospectively reviewed 1162 patients who underwent management for chronic subdural hematoma between May 1998 and March 2025 and included 142 patients with recurrent hematoma (middle meningeal artery embolization in 46 and conventional retreatment in 96) in this study. The primary outcome was second recurrence, defined as a composite of imaging (recurrent or residual hematoma >10 mm in thickness) and clinical (development or aggravation of symptoms, or second re-operation) events. Secondary outcomes included complications (any adverse events or death) and neurological recovery (return of the modified Rankin scale score to the level before initial hematoma development). Outcomes during treatment and 6-month follow-up were compared between the two study groups using logistic regression analysis, adjusted for variables showing baseline group differences with a p-value <0.2.
resultsThe second recurrence rate was significantly lower in patients receiving middle meningeal artery embolization than in those receiving conventional retreatment (1/46 [2.2%] vs. 32/96 [33.3%]; adjusted odds ratio [OR], 0.056; 95% confidence interval [CI], 0.003-0.164; P=0.001). Complication rates did not differ significantly (1/46 [2.2%] vs. 10/96 [10.4%]; adjusted OR, 0.203; 95% CI, 0.019-1.221; P=0.103), but neurological recovery was more frequent in patients receiving middle meningeal artery embolization (32/46 [69.6%] vs. 46/96 [47.9%]; adjusted OR, 3.147; 95% CI, 1.198-8.268; P=0.020).
conclusionMiddle meningeal artery embolization for recurrent chronic subdural hematoma prevented second recurrence and improved neurological recovery compared with conventional retreatment, without increasing the complication rate. These findings suggest that middle meningeal artery embolization could be considered an effective and safe retreatment option for recurrent chronic subdural hematoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.